SCHEMBL13901643

SCHEMBL13901643

CCOC(=O)c1ccc(NC(=O)c2nc(C(Cl)(Cl)Cl)n(-c3ccc(Cl)c(Cl)c3)n2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
ALDH1A1 P00352 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
TP53 P04637 3/20 0.46
HSD17B10 Q99714 2/20 0.46
KDM4E B2RXH2 1/20 0.46
RXFP1 Q9HBX9 1/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
NR3C1 P04150 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPK1 P28482 2/20 0.43
GAA P10253 1/20 0.43
TSHR P16473 1/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13901603 0.85 KMT2A (0.55) MAPTL3MBTL1TP53KMT2AMAPK1
SCHEMBL4015298 0.82 CNR1 (0.43) MAPTALDH1A1KDM4ECNR1CNR2
SCHEMBL13901639 0.80 TP53 (0.49) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL13901636 0.77 POLB (0.50) MAPTALDH1A1NPC1RAB9ARXFP1
SCHEMBL13901640 0.77 RAB9A (0.50) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL13901664 0.77 S1PR5 (0.50) CNR1CNR2
SCHEMBL13901645 0.76 NPY5R (0.48) MAPTALDH1A1L3MBTL1TP53RXFP1
SCHEMBL13901647 0.76 RAB9A (0.48) MAPTALDH1A1NPC1RAB9ATP53
SCHEMBL13901607 0.76 CYP2C19 (0.41) MAPTALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL13901651 0.74 IL2 (0.42) MAPTALDH1A1L3MBTL1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069288-A1 Novel therapeutic compounds ABBVIE INC. 2009-03-12 US disclosed
US-20090069288-A1 Novel therapeutic compounds ABBVIE INC. 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069288-A1 Novel therapeutic compounds MAP3K20, RPS6KB1, MAP3K1 MAPT 3755/4885ALDH1A1 1426/4885L3MBTL1 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.